首页> 外文会议>International Bile Acid Meeting >High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis
【24h】

High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis

机译:高剂量熊毒胆酸治疗原发性胆管炎

获取原文

摘要

Primary sclerosing cholangitis (PSQ is a chronic cholestatic liver disease characterized by a progressive obliterating fibrosis of the intrahepatic and extrahepatic bile ducts. The disease in symptomatic patients often progresses to secondary biliary cirrhosis, and premature death from liver failure, hepatobiliary and colon cancer1. PSC is closely associated with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), which is found in approximately two-thirds of patients with PSC of northern European origin. PSC is the most common hepatobiliary disease associated with UC. The prevalence in UC populations of PSC is between 2 and 6%. There are also associations between PSC and other immune-mediated diseases such as coeliac disease and rheumatoid arthritis.
机译:原发性胆管炎(PSQ是一种慢性胆汁肝病,其特征,其特征在于肝内和肝胆管的渐进式蠕虫纤维化。症状患者的疾病往往对肝脏衰竭,肝胆和结肠癌的过早死亡。PSC与炎症性肠病(IBD),特别是溃疡性结肠炎(UC)密切相关,其在大约三分之二的北欧PSC患者中发现。PSC是与UC相关的最常见的肝胆疾病。UC中的患病率PSC的群体在2和6%之间。PSC和其他免疫介导的疾病如乳腺疾病和类风湿性关节炎的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号